Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
PEARSON, Andrew D J, Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL et. al.
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Authors
PEARSON, Andrew D J (guarantor), Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL, Gregory REAMAN, Rosanna RICAFORT, Delphine HEENEN, Abraham BASSAN, Michael BERNTGEN, Nick BIRD, Eric BLEICKARDT, Najat BOUCHKOUJ, Peter BROSS, Carrie BROWNSTEIN, Sarah Beaussant COHEN, de Rojas TERESA, Lori EHRLICH, Elizabeth FOX, Stephen GOTTSCHALK, Linda HANSSENS, Douglas S HAWKINS, Ivan D HORAK, Danielle H TAYLOR, Courtney JOHNSON, Dominik KARRES, Franca LIGAS, Donna LUDWINSKI, Maksim MAMONKIN, Lynley MARSHALL, Behzad K MASOULEH, Yousif MATLOUB, Shannon MAUDE, Joe MCDONOUGH, Veronique MINARD-COLIN, Koen NORGA, Karsten NYSOM, Alberto PAPPO, Laura PEARCE, Rob PIETERS, Martin PULE, Alfonso QUINTAS-CARDAMA, Nick RICHARDSON, Martina SCHUESSLER-LENZ, Nicole SCOBIE, Martina A SERSCH, Malcolm A SMITH, Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), Sarah K TASIAN, Brenda WEIGEL, Susan L WEINER, Christian Michel ZWAAN, Giovanni LESA and Gilles VASSAL
Edition
European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children.
PEARSON, Andrew D J, Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL, Gregory REAMAN, Rosanna RICAFORT, Delphine HEENEN, Abraham BASSAN, Michael BERNTGEN, Nick BIRD, Eric BLEICKARDT, Najat BOUCHKOUJ, Peter BROSS, Carrie BROWNSTEIN, Sarah Beaussant COHEN, de Rojas TERESA, Lori EHRLICH, Elizabeth FOX, Stephen GOTTSCHALK, Linda HANSSENS, Douglas S HAWKINS, Ivan D HORAK, Danielle H TAYLOR, Courtney JOHNSON, Dominik KARRES, Franca LIGAS, Donna LUDWINSKI, Maksim MAMONKIN, Lynley MARSHALL, Behzad K MASOULEH, Yousif MATLOUB, Shannon MAUDE, Joe MCDONOUGH, Veronique MINARD-COLIN, Koen NORGA, Karsten NYSOM, Alberto PAPPO, Laura PEARCE, Rob PIETERS, Martin PULE, Alfonso QUINTAS-CARDAMA, Nick RICHARDSON, Martina SCHUESSLER-LENZ, Nicole SCOBIE, Martina A SERSCH, Malcolm A SMITH, Jaroslav ŠTĚRBA, Sarah K TASIAN, Brenda WEIGEL, Susan L WEINER, Christian Michel ZWAAN, Giovanni LESA and Gilles VASSAL. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European Journal of Cancer. Oxford: Elsevier Science Inc., 2022, vol. 160, January 2022, p. 112-133. ISSN 0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2021.10.016.
@article{2251959, author = {Pearson, Andrew D J and Rossig, Claudia and Mackall, Crystal and Shah, Nirali N and Baruchel, Andre and Reaman, Gregory and Ricafort, Rosanna and Heenen, Delphine and Bassan, Abraham and Berntgen, Michael and Bird, Nick and Bleickardt, Eric and Bouchkouj, Najat and Bross, Peter and Brownstein, Carrie and Cohen, Sarah Beaussant and Teresa, de Rojas and Ehrlich, Lori and Fox, Elizabeth and Gottschalk, Stephen and Hanssens, Linda and Hawkins, Douglas S and Horak, Ivan D and Taylor, Danielle H and Johnson, Courtney and Karres, Dominik and Ligas, Franca and Ludwinski, Donna and Mamonkin, Maksim and Marshall, Lynley and Masouleh, Behzad K and Matloub, Yousif and Maude, Shannon and McDonough, Joe and MinardandColin, Veronique and Norga, Koen and Nysom, Karsten and Pappo, Alberto and Pearce, Laura and Pieters, Rob and Pule, Martin and QuintasandCardama, Alfonso and Richardson, Nick and SchuesslerandLenz, Martina and Scobie, Nicole and Sersch, Martina A and Smith, Malcolm A and Štěrba, Jaroslav and Tasian, Sarah K and Weigel, Brenda and Weiner, Susan L and Zwaan, Christian Michel and Lesa, Giovanni and Vassal, Gilles}, article_location = {Oxford}, article_number = {January 2022}, doi = {http://dx.doi.org/10.1016/j.ejca.2021.10.016}, keywords = {Paediatric oncology; CAR T-cell; Adoptive cellular immunotherapy; Paediatric Strategy Forum; Drug development; Cancer therapeutics}, language = {eng}, issn = {0959-8049}, journal = {European Journal of Cancer}, title = {Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration}, url = {https://www.sciencedirect.com/science/article/pii/S0959804921011709?via%3Dihub}, volume = {160}, year = {2022} }
TY - JOUR ID - 2251959 AU - Pearson, Andrew D J - Rossig, Claudia - Mackall, Crystal - Shah, Nirali N - Baruchel, Andre - Reaman, Gregory - Ricafort, Rosanna - Heenen, Delphine - Bassan, Abraham - Berntgen, Michael - Bird, Nick - Bleickardt, Eric - Bouchkouj, Najat - Bross, Peter - Brownstein, Carrie - Cohen, Sarah Beaussant - Teresa, de Rojas - Ehrlich, Lori - Fox, Elizabeth - Gottschalk, Stephen - Hanssens, Linda - Hawkins, Douglas S - Horak, Ivan D - Taylor, Danielle H - Johnson, Courtney - Karres, Dominik - Ligas, Franca - Ludwinski, Donna - Mamonkin, Maksim - Marshall, Lynley - Masouleh, Behzad K - Matloub, Yousif - Maude, Shannon - McDonough, Joe - Minard-Colin, Veronique - Norga, Koen - Nysom, Karsten - Pappo, Alberto - Pearce, Laura - Pieters, Rob - Pule, Martin - Quintas-Cardama, Alfonso - Richardson, Nick - Schuessler-Lenz, Martina - Scobie, Nicole - Sersch, Martina A - Smith, Malcolm A - Štěrba, Jaroslav - Tasian, Sarah K - Weigel, Brenda - Weiner, Susan L - Zwaan, Christian Michel - Lesa, Giovanni - Vassal, Gilles PY - 2022 TI - Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration JF - European Journal of Cancer VL - 160 IS - January 2022 SP - 112-133 EP - 112-133 PB - Elsevier Science Inc. SN - 09598049 KW - Paediatric oncology KW - CAR T-cell KW - Adoptive cellular immunotherapy KW - Paediatric Strategy Forum KW - Drug development KW - Cancer therapeutics UR - https://www.sciencedirect.com/science/article/pii/S0959804921011709?via%3Dihub N2 - The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children. ER -
PEARSON, Andrew D J, Claudia ROSSIG, Crystal MACKALL, Nirali N SHAH, Andre BARUCHEL, Gregory REAMAN, Rosanna RICAFORT, Delphine HEENEN, Abraham BASSAN, Michael BERNTGEN, Nick BIRD, Eric BLEICKARDT, Najat BOUCHKOUJ, Peter BROSS, Carrie BROWNSTEIN, Sarah Beaussant COHEN, de Rojas TERESA, Lori EHRLICH, Elizabeth FOX, Stephen GOTTSCHALK, Linda HANSSENS, Douglas S HAWKINS, Ivan D HORAK, Danielle H TAYLOR, Courtney JOHNSON, Dominik KARRES, Franca LIGAS, Donna LUDWINSKI, Maksim MAMONKIN, Lynley MARSHALL, Behzad K MASOULEH, Yousif MATLOUB, Shannon MAUDE, Joe MCDONOUGH, Veronique MINARD-COLIN, Koen NORGA, Karsten NYSOM, Alberto PAPPO, Laura PEARCE, Rob PIETERS, Martin PULE, Alfonso QUINTAS-CARDAMA, Nick RICHARDSON, Martina SCHUESSLER-LENZ, Nicole SCOBIE, Martina A SERSCH, Malcolm A SMITH, Jaroslav ŠTĚRBA, Sarah K TASIAN, Brenda WEIGEL, Susan L WEINER, Christian Michel ZWAAN, Giovanni LESA and Gilles VASSAL. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. \textit{European Journal of Cancer}. Oxford: Elsevier Science Inc., 2022, vol.~160, January 2022, p.~112-133. ISSN~0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2021.10.016.